Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFallon Health Opioid Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentFallon HealthPolicy N/A

    Medicare Opioid Edits and Programs

    Customize your policy alerts

    Sign up for all Fallon Health policy alerts

    Know when Fallon Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Applies to Fallon Health Medicare Part D members, including Fallon Medicare Plus, Navicare, Summit ElderCare PACE, and Fallon Health Weinberg PACE; covers opioid safety edits, medication therapy management, drug management programs, exemptions, and appeal rights.

    Policy Summary
    PayerFallon Health
    PolicyMedicare Opioid Edits and Programs
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionAttest that identified opioid medications, doses, or requested days supply are intended and medically necessary for the member.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7 daysInitial opioid supply limit
    90 MMEOpioid care-coordination threshold
    120 daysOpioid-naive lookback
    30 daysAdvance notice before DMP limitation
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Excluded member categories

    Coverage Criteria

    Point-of-Sale Opioid Safety Edits

    Point-of-sale opioid safety edits apply when a member fills a prescription at the pharmacy. The edits require resolution and continue during the member’s transition period; pharmacists may override certain edits with appropriate codes, consult the prescriber, or notify the prescriber that prior authorization is required.

    POS opioid safety edits

    • Soft edits — pharmacy may override

      • Concurrent opioid and benzodiazepine use.
      • Duplicative long-acting (LA) opioid therapy.
      • Concurrent opioid and prenatal vitamin use.
      • Concurrent opioid and Medication-Assisted Therapy (MAT) use.
    • Care coordination edit at ≥ 90 morphine milligram equivalents (MME) and 2 prescribers; the pharmacy may override only after consulting the prescriber, documenting the discussion, and confirming that the opioid(s) and/or day supply are intended and medically necessary for the member. The override must use a code indicating that the prescriber was consulted.
    • Hard edit limiting initial opioid fills for opioid-naïve members to a 7-day supply, using a 120-day lookback. A member is opioid-naïve when there are no opioid claims in the previous 120 days. If the pharmacy cannot resolve the edit at point of sale, prior authorization is required, and the provider must attest that the opioid(s) and/or day supply are intended and medically necessary.
    • For members age 18 or older, concurrent opioid and benzodiazepine use for more than 14 days; if the pharmacy cannot resolve the edit at point of sale, prior authorization is required.

    Drug Management Program Identification

    Members may be identified for the Drug Management Program (DMP) when any one of the following criteria is met. The program is a retrospective drug utilization review process for members at risk from frequently abused drugs, defined by CMS as opioids and benzodiazepines.

    Any DMP identification criterion

    • ALL of the following

      • Opioid pharmacy claims totaling ≥ 90 MME.
      • Three or more opioid prescribers.
      • Three or more opioid dispensing pharmacies.
    • ALL of the following

      • Opioid pharmacy claims totaling ≥ 90 MME.

    Medication Therapy Management Eligibility

    Medication Therapy Management (MTMP) is not applicable to PACE. In addition to traditional MTMP eligibility, members are eligible when identified as an At-Risk Beneficiary (ARB) under a Drug Management Program (DMP).

    MTMP eligibility

    • Meets traditional MTMP eligibility criteria.
    • Has been identified as an At-Risk Beneficiary (ARB) under a Drug Management Program (DMP).

    The following members are excluded from the POS opioid safety edits and related drug management interventions: members receiving hospice, palliative, end-of-life care, or other palliative care; members being treated for active cancer-related pain; members with sickle cell disease; and residents of long-term care facilities.

    Members have Coverage Determination and Appeal rights under the POS opioid safety-edit program. Members have appeal rights under the Drug Management Program.

    Buprenorphine used for medication-assisted treatment (MAT) is not included in the POS opioid safety edits and should not impact enrollee access to MAT. Buprenorphine for MAT is also excluded from the 90 MME accumulations used in the Drug Management Program.

    Thresholds and Program Rules

    Opioid care coordination
    ThresholdAt least 90 MME per day
    Fallon POS triggerCare coordination at 90 MME with 2 prescribers
    ResolutionPharmacy override requires prescriber consultation, documentation of the discussion, confirmation of intent, and an appropriate override code
    Initial opioid supply
    LimitUp to a 7-day supply for an initial opioid fill
    Applies toOpioid-naive members
    If unresolvedA prior authorization or coverage determination may be required when the pharmacy cannot resolve the hard edit at point of sale

    Provider and Pharmacy Actions

    Prior Authorization

    Resolve Unresolved Safety Edits

    If the pharmacy cannot resolve an opioid safety edit at point of sale, pursue the applicable coverage determination or prior authorization before the prescription is dispensed. CMS expects Part D plans to maintain a process for resolving or overriding opioid safety alerts at the pharmacy based on prescriber information or an enrollee exemption.

    • Contact Fallon Health to submit a coverage determination or exception request: 1-844-657-0494; Fallon Health Weinberg PACE: 1-844-722-1701; fax: 844-403-1028.
    Prior Authorization

    Request a Coverage Determination

    An enrollee or prescriber may request a standard or expedited coverage determination for the drug or requested quantity, including in advance of prescribing. Use this process when an opioid safety alert cannot otherwise be resolved or when the full days supply is needed.

    • The prescriber may request a determination on the enrollee’s behalf.
    • A standard or expedited request may be submitted.

    Policy Background

    Fallon Health uses pharmacy claim safety edits at the point of sale and a retrospective Drug Management Program to identify potentially unsafe opioid utilization. The safety framework addresses patterns such as high cumulative morphine milligram equivalent exposure, multiple prescribers or pharmacies, concurrent benzodiazepine use, and opioid-related overdose history. These interventions are safety mechanisms and do not replace individualized clinical judgment.

    Key Definitions

    Opioid naive
    DefinitionA member with no opioid claims during the applicable lookback period
    Fallon POS lookback120 days
    Prescriber informationRecent opioid use may also be described as use within the past 60 days for the alert
    At-Risk Beneficiary (ARB)
    DefinitionA member identified by the plan as at risk for prescription drug abuse or misuse
    Program involvementThe member is subject to case management and clinical outreach
    Potential limitations

    Initial Opioid Therapy

    Initial Opioid Supply Limit

    The initial opioid fill is subject to a hard point-of-sale edit when all of the following are met:

    Initial opioid fill

    • The member has no opioid claims in the prior 120 days and is therefore considered opioid naive.120-day lookback
    • The requested initial opioid prescription exceeds a 7-day supply.> 7 days

    Continuation of Opioid Therapy

    Continuation After Initial Opioid Fill

    Subsequent opioid prescriptions are not subject to the initial 7-day limit when all of the following are met:

    Continuation after initial opioid fill

    • The member has an opioid claim within the plan's applicable lookback window and is no longer considered opioid naive.Prior opioid claim within the applicable lookback window

    Quantity Limits

    Initial opioid fills
    Quantity limitUp to 7 days per initial opioid fill
    Applies whenThe member is opioid naive and has no opioid claims in the prior 120 days
    Edit typeA hard point-of-sale edit; unresolved claims may require prior authorization or a coverage determination
    Policy Summary
    PayerFallon Health
    PolicyMedicare Opioid Edits and Programs
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionAttest that identified opioid medications, doses, or requested days supply are intended and medically necessary for the member.
    SourceLink
    On This Page
    Coverage CriteriaThresholds and Program RulesProvider and Pharmacy ActionsPolicy BackgroundKey DefinitionsInitial Opioid TherapyContinuation of Opioid TherapyQuantity Limits
    Five or more opioid prescribers.
  1. ANY of the following

    • Any MME level and seven or more opioid prescribers.
    • Any MME level and seven or more opioid dispensing pharmacies.
  2. A history of opioid-related overdose.
  3. Program operations after identification

    • Case management and clinical outreach to providers are conducted to determine whether the member is at risk for opioid overutilization.
    • The member is notified.
    • The member may be subject to lock-in restrictions to specific provider(s), pharmacy(ies), and/or at the drug level.
    • Members have appeal rights under the DMP.
    • Dual/Low Income Subsidy (LIS) members have limited ability to change plans to avoid intervention once identified as at risk.
    Opioid-naive lookback
    Lookback periodPrevious 120 days
    Opioid-naive statusThe member has no opioid claims during the previous 120 days
    ContinuationSubsequent opioid prescriptions within the plan’s lookback window are not subject to the initial 7-day limit
    Opioid and benzodiazepine concurrency
    Age requirementMembers age 18 or older
    Concurrent therapyOpioid and benzodiazepine use
    Duration thresholdGreater than 14 days; unresolved edits may require prior authorization
    DMP identification by prescribers and pharmacies
    Opioid exposureAt least 90 MME
    Prescribers3 or more opioid prescribers
    Dispensing pharmacies3 or more opioid dispensing pharmacies
    DMP identification by prescribers
    Opioid exposureAt least 90 MME
    Prescriber threshold5 or more opioid prescribers
    Program responseIdentification may lead to case management, clinical outreach, and potential restrictions
    DMP identification at any MME
    MME thresholdAny MME level
    Prescriber threshold7 or more opioid prescribers
    Pharmacy threshold7 or more opioid dispensing pharmacies
    Optional opioid safety alert
    Alert thresholdAt least 200 MME per day
    AvailabilitySome plans may implement this optional safety alert
    ResolutionResolution generally requires plan processing of a coverage determination and prescriber attestation of intended medical necessity

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Prior Authorization

    Concurrent Opioid and Benzodiazepine Use

    For members age 18 or older with concurrent opioid and benzodiazepine use exceeding 14 days, the pharmacy may encounter a benzodiazepine concurrent-use edit. If it cannot be resolved at point of sale, submit the required prior authorization or coverage determination.

    • Review the clinical need for concurrent opioid and benzodiazepine therapy and provide supporting information with the request.
    Denial Risk

    Resolve an Unresolved Opioid Safety Edit

    When an opioid safety edit remains unresolved, work with the pharmacy and plan to determine whether prescriber consultation, medical-necessity documentation, and an applicable override code will resolve it. If the edit cannot be resolved at point of sale, pursue a prior authorization or coverage determination rather than allowing an avoidable interruption in therapy.

    • CMS expects opioid safety alerts, including hard edits, to have a point-of-sale resolution or override mechanism.
    • Provide information showing whether the member is exempt or whether the prescribed therapy is intended and medically necessary.

    Unsupported block type: denial_risk

    Access may be limited to specified prescribers, pharmacies, or drugs
    Drug Management Program (DMP)
    Program nameDrug Management Program under the Comprehensive Addiction and Recovery Act of 2016
    PurposeA retrospective drug utilization review program that identifies members at risk for misuse of opioids or benzodiazepines
    Program activityConducts case management and clinical outreach
    Medication-Assisted Treatment (MAT)
    DefinitionMedication-assisted treatment, including buprenorphine
    ExclusionBuprenorphine used for MAT is not included in the point-of-sale opioid safety edits
    MME accumulationBuprenorphine used for MAT is not included in the 90 MME accumulation